Oxford 1st October 2018;Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Hao Zhang as Vice President Business Development and Commercialisation. Hao has extensive experience in the Biotech arena, and has worked in both pharmaceutical and diagnostics, after completing his training in Oxford and Harvard.
Prior to Celleron Therapeutics, Hao played a key role in the commercial launch of cancer medicines at Roche and in the clinical development with a precision medicine approach at AstraZeneca. He has broad experience in lifecycle management of medicinal development and commercialisation, as well as in expanding business in both emerging and developed markets. His recent interest includes healthcare informatics and the interplay between information technology and medicine.
“We are very pleased to be appointing Hao to this key position as we build both our clinical operations and drug development capability to advance CXD101 into Phase 2 trials into China and to develop key partnerships across the region” commented CEO Prof Nick La Thangue.
About Celleron Therapeutics
Celleron Therapeutics, based on the Oxford Science Park, UK, is a drug development company focussed on precision medicine for cancer. It is a spin-out of Oxford University and has secured a number of exclusive licence agreements with pharmaceutical companies, including Astra Zeneca. Celleron’s precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects in tumour cells, and CXD201 represents a new type of topoisomerase inhibitor.
Download the Press Release here: